Posted by Michael Wonder on 12 Sep 2018
Sunovion announces Health Canada acceptance of new drug submission for apomorphine sublingual film (APL-130277)
12 September 2018 - Sunovion seeks approval for apomorphine sublingual film for the on-demand treatment of OFF episodes associated with Parkinson’s disease.
Sunovion announced today that Health Canada has accepted the new drug submission for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes), experienced by people living with Parkinson’s disease, including those who experience early morning OFF episodes.
Apomorphine sublingual film (APL-130277), a novel formulation of apomorphine, a non-ergot dopamine agonist, is being developed as a fast-acting sublingual film for the on-demand management of OFF episodes associated with Parkinson’s disease.
